Tiziana Life Sciences to Host Investor Call
Dial-in details and webcast information will be provided on the morning of
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
646.970.4681
ikoffler@lifesciadvisors.com
![](https://ml.globenewswire.com/media/ZGQ5M2U2YTItMWVkNy00ZWVjLThhNjAtODA1MmQ1Nzg0ODY4LTExMzU0NTY=/tiny/Tiziana-Life-Sciences-Plc.png)
Source: Tiziana Life Sciences Ltd.